Lumigan is indicated for use, either as monotherapy or with β-blockers, to reduce elevated IOP in adults with chronic open-angle glaucoma or ocular hypertension.
Bimatoprost is a prostaglandin analogue. It reduces IOP by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.
A pivotal, 12-month, randomised, controlled trial showed bimatoprost 0.1mg/ml to be equivalent in efficacy to bimatoprost 0.3mg/ml for the once-daily treatment of glaucoma or ocular hypertension. Both preparations reduced mean IOP by approximately 30% after 12 months.1
Patients treated with bimatoprost 0.1mg/ml were significantly less likely to experience treatment-related ocular adverse events than those treated with bimatoprost 0.3mg/ml (37.8% versus 50.3%; p=0.016). The relative risk of treatment discontinuation due to ocular adverse effects was 66 per cent lower in the bimatoprost 0.1mg/ml group than in the bimatoprost 0.3mg/ml group.
- Cohen JS et al. Poster presented at 8th Congress of the European Glaucoma Society. Berlin, Germany, June 2008; P106.
Further information: Allergan